Myomo Inc (MYO)
Official siteHEALTHCARE • MEDICAL DEVICES • AMEX
Market Cap: $49.32M
Last updated: Nov 17, 2026 at 11:05 AM ET
Myomo Inc (MYO) Earnings: Report Dates and Results
Myomo (MYO) is confirmed to report earnings on Mar 8, 2027, after the close. In the quarter ended Sep 30, 2026, Myomo reported EPS of -$0.07, above the -$0.08 estimate. It beat the EPS estimate in 5 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
MYO has a confirmed report date of Mar 8, 2027, after the close.
MYO Earnings Call
The latest MYO earnings call transcript on file is labeled 2026Q1.
Read the 2026Q1 transcriptEarnings History
Of the 37 quarters below that had an estimate, MYO beat 26, missed 9 and matched 2. Revenue for the quarter ended Sep 30, 2026 was $12.33M, up 22.2% from $10.09M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.07 | -$0.08 | -$0.08 - -$0.07 | +12.50% | Beat | N/A | 3 | 2 up, 1 down | Nov 9, 2026 | $12.33M |
| Jun 30, 2026 | -$0.07 | -$0.10 | -$0.11 - -$0.09 | +30.00% | Beat | N/A | 3 | 0 up, 2 down | Aug 5, 2026 | $11.70M |
| Mar 31, 2026 | -$0.09 | -$0.11 | -$0.13 - -$0.10 | +18.18% | Beat | N/A | 4 | 0 up, 3 down | May 7, 2026 | $10.11M |
| Dec 31, 2025 | -$0.09 | -$0.08 | -$0.09 - -$0.08 | -1.43% | Miss | N/A | 4 | 0 up, 4 down | Mar 9, 2026 | $11.35M |
| Sep 30, 2025 | -$0.09 | -$0.11 | -$0.12 - -$0.10 | +18.18% | Beat | N/A | 5 | 0 up, 2 down | Nov 10, 2025 | $10.09M |
| Jun 30, 2025 | -$0.11 | -$0.11 | -$0.12 - -$0.10 | 0.00% | In line | N/A | 5 | 0 up, 5 down | Aug 11, 2025 | $9.65M |
| Mar 31, 2025 | -$0.08 | -$0.08 | -$0.09 - -$0.06 | 0.00% | In line | N/A | 5 | 1 up, 2 down | May 7, 2025 | $9.83M |
| Dec 31, 2024 | -$0.01 | -$0.02 | -$0.04 - -$0.01 | +57.08% | Beat | N/A | 6 | 0 up, 1 down | Mar 10, 2025 | $12.07M |
| Sep 30, 2024 | -$0.03 | -$0.04 | -$0.06 - -$0.03 | +25.00% | Beat | N/A | 6 | 0 up, 0 down | Nov 6, 2024 | $9.21M |
| Jun 30, 2024 | -$0.03 | -$0.07 | -$0.09 - -$0.06 | +57.14% | Beat | N/A | 6 | 3 up, 0 down | Aug 6, 2024 | $7.52M |
| Mar 31, 2024 | -$0.10 | -$0.09 | -$0.10 - -$0.09 | -11.11% | Miss | N/A | 3 | 0 up, 0 down | May 8, 2024 | $3.75M |
| Dec 31, 2023 | -$0.07 | -$0.06 | -$0.06 - -$0.05 | -16.67% | Miss | N/A | 4 | 0 up, 0 down | Mar 7, 2024 | $4.76M |
| Sep 30, 2023 | -$0.06 | -$0.09 | -$0.10 - -$0.08 | +33.33% | Beat | N/A | 4 | 0 up, 0 down | Nov 7, 2023 | $5.08M |
| Jun 30, 2023 | -$0.04 | -$0.03 | -$0.05 - -$0.02 | -33.33% | Miss | N/A | 4 | 0 up, 0 down | Aug 9, 2023 | $5.96M |
| Mar 31, 2023 | -$0.11 | -$0.13 | -$0.15 - -$0.12 | +15.38% | Beat | N/A | 4 | 0 up, 0 down | May 10, 2023 | $3.45M |
| Dec 31, 2022 | -$0.29 | -$0.42 | -$0.44 - -$0.38 | +30.95% | Beat | N/A | 4 | 0 up, 0 down | Mar 13, 2023 | $4.04M |
| Sep 30, 2022 | -$0.40 | -$0.43 | -$0.53 - -$0.38 | +6.98% | Beat | N/A | 4 | 0 up, 0 down | Nov 10, 2022 | $3.97M |
| Jun 30, 2022 | -$0.42 | -$0.43 | -$0.53 - -$0.37 | +2.33% | Beat | N/A | 4 | 0 up, 0 down | Aug 3, 2022 | $3.68M |
| Mar 31, 2022 | -$0.41 | -$0.53 | -$0.60 - -$0.46 | +22.64% | Beat | N/A | 4 | 0 up, 0 down | May 11, 2022 | $3.87M |
| Dec 31, 2021 | -$0.52 | -$0.49 | -$0.53 - -$0.44 | -6.12% | Miss | N/A | 5 | N/A | Mar 9, 2022 | N/A |
| Sep 30, 2021 | -$0.36 | -$0.46 | -$0.56 - -$0.41 | +21.74% | Beat | N/A | 5 | 4 up, 0 down | Nov 10, 2021 | $4.38M |
| Jun 30, 2021 | -$0.46 | -$0.61 | -$0.70 - -$0.52 | +24.59% | Beat | N/A | 5 | N/A | Aug 9, 2021 | $3.10M |
| Mar 31, 2021 | -$0.57 | -$0.68 | -$0.77 - -$0.58 | +16.18% | Beat | N/A | 4 | N/A | May 5, 2021 | $2.34M |
| Dec 31, 2020 | -$0.37 | -$0.49 | -$0.56 - -$0.37 | +24.49% | Beat | N/A | 4 | N/A | Mar 10, 2021 | $3.79M |
| Sep 30, 2020 | -$0.66 | -$1.05 | -$1.28 - -$0.83 | +37.14% | Beat | N/A | 4 | N/A | Nov 10, 2020 | $1.93M |
| Jun 30, 2020 | -$1.02 | -$1.34 | -$1.36 - -$1.13 | +23.88% | Beat | N/A | 4 | N/A | Aug 10, 2020 | $858590 |
| Mar 31, 2020 | -$2.47 | -$2.32 | -$2.34 - -$1.54 | -6.47% | Miss | N/A | 3 | N/A | May 14, 2020 | $1.01M |
| Dec 31, 2019 | -$4.61 | -$4.59 | -$4.80 - -$4.48 | -0.44% | Miss | N/A | 3 | N/A | Mar 12, 2020 | $1.52M |
| Sep 30, 2019 | -$4.80 | -$4.95 | -$5.11 - -$4.50 | +3.03% | Beat | N/A | 3 | N/A | Nov 12, 2019 | $606619 |
| Jun 30, 2019 | -$4.50 | -$5.10 | N/A | +11.76% | Beat | N/A | 2 | N/A | Aug 8, 2019 | $880349 |
| Mar 31, 2019 | -$5.10 | -$6.00 | N/A | +15.00% | Beat | N/A | 1 | N/A | May 13, 2019 | $830066 |
| Dec 31, 2018 | -$6.51 | -$7.50 | N/A | +13.20% | Beat | N/A | 1 | N/A | Mar 7, 2019 | $889575 |
| Sep 30, 2018 | -$6.43 | -$6.90 | N/A | +6.81% | Beat | N/A | 1 | N/A | Nov 5, 2018 | $608981 |
| Jun 30, 2018 | -$6.36 | -$5.40 | -$6.01 - -$5.11 | -17.78% | Miss | N/A | 2 | N/A | Aug 7, 2018 | $632369 |
| Mar 31, 2018 | -$5.95 | -$5.70 | -$5.71 - -$5.41 | -4.39% | Miss | N/A | 2 | N/A | May 9, 2018 | $313179 |
| Dec 31, 2017 | -$7.20 | -$9.90 | N/A | +27.27% | Beat | N/A | 1 | N/A | Mar 7, 2018 | $547412 |
| Sep 30, 2017 | -$6.30 | -$9.00 | N/A | +30.00% | Beat | N/A | N/A | N/A | Nov 6, 2017 | $488540 |
| Jun 30, 2017 | -$0.24 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Aug 14, 2017 | $306683 |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$0.37, after -$0.17 the year before. It was -$13.74 for the year ended Dec 31, 2017, the oldest of the 9 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$0.37 | N/A |
| Dec 31, 2024 | -$0.17 | N/A |
| Dec 31, 2023 | -$0.28 | N/A |
| Dec 31, 2022 | -$1.52 | N/A |
| Dec 31, 2021 | -$1.91 | N/A |
| Dec 31, 2020 | -$4.52 | N/A |
| Dec 31, 2019 | -$19.01 | N/A |
| Dec 31, 2018 | -$25.25 | N/A |
| Dec 31, 2017 | -$13.74 | N/A |
Earnings Calls
The 6 most recent earnings calls are listed below; the latest, 2026Q1 for the period ended Mar 31, 2026, runs about 4,700 words across 7 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q1 | Mar 31, 2026 | 4,690 | 7 | |
| 2025Q3 | Sep 30, 2025 | 5,658 | 9 | |
| 2025Q2 | Jun 30, 2025 | 6,720 | 9 | |
| 2025Q1 | Mar 31, 2025 | 6,337 | 9 | |
| 2024Q3 | Sep 30, 2024 | 5,748 | 9 | |
| 2024Q2 | Jun 30, 2024 | 5,191 | 9 |
2026Q1 Earnings Call
Opening remarks
Bruce Voss Investor Relations Thank you and good afternoon, everybody. This is Bruce Voss with Alliance Advisors IR. Welcome to the Myomo, Inc. First Quarter 2026 Financial Results Conference Call. With me on today's call are Myomo, Inc.'s Chief Executive Officer, Paul R. Gudonis, and Chief Financial Officer, David A. Henry. Before we begin, I would like to caution listeners that statements made during this call by management other than historical facts are forward-looking statements. The words anticipate, believe, estimate, expect, intend, guidance, outlook, confidence, target, project and other similar expressions are typically used to identify such forward-looking statements. These forward-looking statements are not guarantees of future performance and may involve and are subject to risks, uncertainties and other factors that may affect Myomo, Inc.'s business, financial condition and operating results. These risks, uncertainties and other factors are discussed in Myomo, Inc.'s filings with the Securities and Exchange Commission. Actual outcomes and results may differ materially from what is expressed in or implied by these forward-looking statements. Furthermore, except as required by law, Myomo, Inc. undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this call today, 05/07/2026. Now it is my pleasure to turn the call over to Myomo, Inc.'s CEO, Paul. Paul, please go ahead.
Paul R. Gudonis Chief Executive Officer Thanks, Bruce. Well, good afternoon, and thank you all for joining us today. We remain very excited about the opportunity in front of us to improve lives and grow our company. Chronic upper-limb paralysis is an underserved medical condition and each year stroke leaves hundreds of thousands of Americans with long-lasting arm impairments. When you add in spinal cord injury, traumatic brain injury and brachial plexus injuries, the addressable U.S. population reaches into the millions, and globally millions more. For most of these patients, the standard of care has been a passive brace, ongoing physical therapy with diminishing returns, or resignation to permanent loss of function. Our MyoPro is the only commercially available powered arm orthosis in the U.S. that uses non-invasive EMG sensors to detect the patient's own muscle signals and amplify them into functional movement, thereby permitting paralyzed individuals to feed themselves, carry objects, return to work, and reclaim independence at home. It is not an incremental improvement on existing care. It is really an entirely different category of device and Myomo, Inc. owns it. Let me start with a quick real-life story.
Frequently Asked Questions About MYO
When is Myomo's next earnings date?
Myomo's next earnings report is confirmed for Mar 8, 2027, after the close.
Did MYO beat earnings estimates last quarter?
Yes. Myomo reported EPS of -$0.07 for the quarter ended Sep 30, 2026, above the -$0.08 estimate, a 12.50% surprise.
What EPS do analysts expect from MYO next quarter?
The consensus EPS estimate for Myomo for the quarter ending Dec 31, 2026 is -$0.07 from 6 analysts, with estimates from -$0.08 to -$0.06.
How often does MYO beat earnings estimates?
Myomo beat the EPS estimate in 5 of the last 8 quarters, with an average surprise of +16.81%.
Does MYO report before or after the market opens?
Myomo is confirmed to report on Mar 8, 2027, after the market closes.
MYO pages: Overview, Earnings, Forecast, Financials, Competitors, Government Contracts